Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs TransMedics Group Inc (TMDX) Price & Performance

Novartis AGTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs TransMedics Group Inc — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Novartis AG is far larger — about 95.3× TransMedics Group Inc's market cap, and Novartis AG pays a 3.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

NVSTMDX
Market Cap
$295.37B$3.10B
Sector
HealthTechnology
52-Week High
$168.62$150.42
52-Week Low
$119.31$61.99
Enterprise Value
$336.69B$3.49B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX